VRCA insider trading
NasdaqCM HealthcareVerrica Pharmaceuticals Inc.: insider trade history from SEC Form 4 filings.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Company website: www.verrica.com
VRCA insider activity at a glance
FilingIQ tracks 340 insider transactions for VRCA in filings since Jun 19, 2018. The most recent transaction is dated Aug 18, 2026.
Across the full history, 85 open-market purchases
and 218 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VRCA insider trades is 54.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VRCA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading VRCA
Frequently asked
- How many insider trades does FilingIQ track for VRCA?
- FilingIQ tracks 340 Form 4 insider transactions for VRCA (Verrica Pharmaceuticals Inc.), covering filings from Jun 19, 2018 onwards. 6 of those are dated within the last 90 days.
- Are VRCA insiders net buyers or net sellers?
- Across the full Form 4 history for VRCA, 85 transactions (25%) were open-market purchases and 218 (64%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VRCA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is VRCA in?
- Verrica Pharmaceuticals Inc. (VRCA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $79.37M.
Methodology & sources
Every VRCA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.